INS and hyperlipidemia: The metabolic dysfunctions in cancer (described in detail in Section 3.1, Section 3.2, Section 3.3, Section 3.4 and Section 3.5) include reduced insulin sensitivity, hyperlipidemia, impaired mitochondrial function, chronic inflammation, and cancer cachexia (Figure 1).